PD-1 plus chemo for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a locally advanced (stage III or IV) head or neck cancer that is poorly differentiated (fast-growing cells), in areas like the throat, voice box, or sinuses, but not nasopharyngeal cancer.
- You haven't had a PD-1/PD-L1 drug combined with chemotherapy before.
- You are at least 18 years old, with a good performance status (able to do most daily activities).
- Your blood counts, kidney, and liver function are within certain limits (checked by blood tests).
- You do not have active infections like HIV or hepatitis, uncontrolled medical conditions, or a history of certain other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
This trial tests giving a combination of targeted immunotherapy and chemotherapy before surgery for people with advanced head and neck cancer (stage 3 or 4a). The goal is to see if this pre-treatment can shrink tumors and improve outcomes.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.